Arrowhead pharmaceuticals initiates phase 1/2a study of aro-alk7 for the treatment of obesity

Pasadena, calif.--(business wire)---- $arwr--arrowhead pharmaceuticals, inc. (nasdaq: arwr) today announced that it has dosed the first subjects in a phase 1/2a clinical trial of aro-alk7, the company's investigational rna interference (rnai) therapeutic being developed as a potential treatment for obesity. aro-alk7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. the study initiates in otherwise healthy obese subjects using single and multiple escalating.
ALK Ratings Summary
ALK Quant Ranking